Resource Summary Report

Generated by ASWG on Aug 9, 2026

Brilliant Violet 785(TM) anti-human CD8

RRID:AB_2566202
Type: Antibody

Proper Citation

BioLegend Cat# 344740, RRID:AB_2566202

Antibody Information

URL: http://antibodyregistry.org/AB_2566202

Proper Citation: BioLegend Cat# 344740, RRID:AB_2566202

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2566202

Vendor: BioLegend

Catalog Number: 344740

Alternative Catalog Numbers: 344739

Record Creation Time: 20250819T224441+0000

Record Last Update: 20250820T031002+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-human CD8.

No alerts have been found for Brilliant Violet 785(TM) anti-human CD8.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

Len-Tayon K, et al. (2026) Impaired vitamin D signaling reveals neutrophils as key drivers of prostate cancer dissemination. EMBO molecular medicine, 18(5), 1967.

Dodd KC, et al. (2026) Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis. Med (New York, N.Y.), 7(3), 100987.

Magno JC, et al. (2026) Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. Cancer research, 86(11), 2688.

Stockmann AP, et al. (2025) DF6215, an ?-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. Cell reports. Medicine, 102518.

Laheurte C, et al. (2025) UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity. Cell reports. Medicine, 6(7), 102196.

Kirk AM, et al. (2024) DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell reports. Medicine, 5(3), 101469.

Motte J, et al. (2024) Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. Neuron, 112(11), 1757.

Ciacchi L, et al. (2023) CD4+ T cell-mediated recognition of a conserved cholesterol-dependent cytolysin epitope generates broad antibacterial immunity. Immunity, 56(5), 1082.

Parry EM, et al. (2023) ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer cell, 41(10), 1803.

Alam A, et al. (2022) Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer cell, 40(2), 153.

Zheng C, et al. (2022) Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. Cancer cell, 40(4), 410.

Krämer B, et al. (2021) Early IFN-? signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity, 54(11), 2650.

Mogilenko DA, et al. (2021) Comprehensive Profiling of an Aging Immune System Reveals Clonal GZMK+ CD8+ T Cells as Conserved Hallmark of Inflammaging. Immunity, 54(1), 99.

Shuwa HA, et al. (2021) Alterations in T and B cell function persist in convalescent COVID-19 patients. Med (New York, N.Y.), 2(6), 720.

De Domenico E, et al. (2020) Optimized workflow for single-cell transcriptomics on infectious diseases including COVID-19. STAR protocols, 1(3), 100233.

Schulte-Schrepping J, et al. (2020) Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell, 182(6), 1419.